Argumentum Pharma will allocate 1.8 billion rubles for the production of drugs from the list of vital and essential drugs

The Agrumentum Pharma enterprise will be located on an area of 8 thousand square meters and will produce drugs for stabilizing blood pressure during surgical interventions, for the treatment of arterial hypertension, tachycardia, myocardial infarction, as well as for the treatment of pain syndrome, including pain relief during childbirth.

The enterprise will be equipped with automated bottling and packaging lines, ensuring the filling of vials, ampoules and syringes without operator intervention.

Argumentum Pharma announced the production of medicines in the SEZ, including drugs from the list of vital and essential drugs, in August 2021. The project was planned to be implemented in two stages at that time: the first stage of production was to be commissioned by the end of 2023, and the full launch of capacities was to start within four years. The total investment in the project in 2021 was estimated at more than 1.5 billion rubles.

In July 2025, it became known that in the Dubna SEZ, the Alsigma company (part of Altegra JSC) is implementing a project to create the production of antitumor drugs, hormone antagonists and related compounds. The investment volume will be 1.8 billion rubles.